Target and Its Patented Drug(s)
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T17566 | Target Info | |||
| Target Name | RET V804L mutant (RET V804L) | ||||
| Synonyms | RET51 V804L mutant; Proto-oncogene tyrosine-protein kinase receptor Ret V804L mutant; Proto-oncogene c-Ret V804L mutant; PTC V804L mutant; Cadherin family member 12 V804L mutant; CDHR16 V804L mutant; CDHF12 V804L mutant | ||||
| Target Type | Patented-recorded Target | ||||
| Gene Name | RET | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | |||||
| Patent ID | WO2014050781 | ||||
| Title | Ret Inhibitor. | ||||
| Abstract | A compound represented by general formula (I) (the symbols in the formula are as defined in the description), a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can be used as an agent for the prevention or treatment of disorders including cancers and cancer metastases having mutations in RET. | ||||
| Applicant(s) | Chugai Pharmaceutical Co., Ltd | ||||
| Representative Drug(s) | D0O9JD | Drug Info | IC50 = 32 nM | [1] | |
| United States Patent and Trademark Office (USPTO) | |||||
| Patent ID | US20140272958 | ||||
| Title | Ret Inhibitor. | ||||
| Applicant(s) | Chugai Pharmaceutical | ||||
| Representative Drug(s) | D0O9JD | Drug Info | IC50 = 32 nM | [1] | |
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.